Sunshine Biopharma Inc.
SBFM Nasdaq
SEC CIK 1402328
Follow Sunshine Biopharma
Weekly email: filings, results
Revenue, last quarter
$9.4M
+0.3% vs same quarter last year
Net income
−$1.2M
−38.5% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$1.4M
−85.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $36.3M | −$6M |
| FY24 | $34.9M | −$5.1M |
| FY23 | $24.1M | −$4.5M |
| FY22 | $4.3M | −$26.7M |
| FY21 | $228.4K | −$12.4M |
| FY20 | $71.4K | −$2.8M |
| FY19 | $21.1K | −$1.7M |
| FY18 | $0 | −$2.2M |
| FY17 | $0 | −$1M |
| FY16 | $0 | −$3.5M |
| FY15 | $1.7K | −$1.7M |
| FY14 | $0 | −$1.9M |
| FY13 | $0 | −$2.5M |
| FY12 | $0 | −$708K |
| FY11 | $0 | −$556.2K |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 33.8% | −17.2% | −16.5% |
| FY24 | 30.6% | −16.7% | −14.7% |
| FY23 | 34.6% | −19.9% | −18.7% |
| FY22 | 39% | −621.3% | −615.4% |
| FY21 | 48.4% | −1068.2% | −5444.4% |
| FY20 | 63.8% | −807.8% | −3898.7% |
| FY19 | 47.7% | −3037.9% | −7860.9% |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | - | −45683.7% | −96774.5% |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$5.5M |
| FY24 | −$14.2M |
| FY23 | −$8.9M |
| FY22 | −$5.4M |
| FY21 | −$1.8M |
| FY20 | −$658.5K |
| FY19 | −$496.7K |
| FY18 | −$531.7K |
| FY17 | −$547.2K |
| FY16 | −$317.6K |
| FY15 | −$872.4K |
| FY14 | −$538.6K |
| FY13 | - |
| FY12 | - |
| FY11 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $0 |
| FY24 | $3.1M |
| FY23 | $541.1K |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Sunshine Biopharma
- Healthcare median
Show the numbers
| Year | Sunshine Biopharma | Healthcare median |
|---|---|---|
| FY25 | −16.5% | −30.6% |
| FY24 | −14.7% | −47% |
| FY23 | −18.7% | −58% |
| FY22 | −615.4% | −80.4% |
| FY21 | −5444.4% | −71.8% |
| FY20 | −3898.7% | −62.2% |
| FY19 | −7860.9% | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | −96774.5% | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |